Cargando…
Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Glaucoma is the leading cause of irreversible blindness worldwide. Therapies for glaucoma are directed toward reducing intraocular pressure (IOP), the leading risk factor and only reliable therapeutic target via topical medications or with procedural intervention including laser or surgery. Though t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154118/ https://www.ncbi.nlm.nih.gov/pubmed/35639753 http://dx.doi.org/10.1371/journal.pone.0269261 |
_version_ | 1784717973205811200 |
---|---|
author | Roddy, Gavin W. Roy Chowdhury, Uttio Anderson, Kjersten J. Rinkoski, Tommy A. Hann, Cheryl R. Chiodo, Vince A. Smith, W. Clay Fautsch, Michael P. |
author_facet | Roddy, Gavin W. Roy Chowdhury, Uttio Anderson, Kjersten J. Rinkoski, Tommy A. Hann, Cheryl R. Chiodo, Vince A. Smith, W. Clay Fautsch, Michael P. |
author_sort | Roddy, Gavin W. |
collection | PubMed |
description | Glaucoma is the leading cause of irreversible blindness worldwide. Therapies for glaucoma are directed toward reducing intraocular pressure (IOP), the leading risk factor and only reliable therapeutic target via topical medications or with procedural intervention including laser or surgery. Though topical therapeutics are typically first line, less than 50% of patients take drops as prescribed. Sustained release technologies that decrease IOP for extended periods of time are being examined for clinical use. We recently identified Stanniocalcin-1, a naturally occurring hormone, as an IOP-lowering agent. Here, we show that a single injection into the anterior chamber of mice with an adeno-associated viral vector containing the transgene of stanniocalcin-1 results in diffuse and sustained expression of the protein and produces IOP reduction for up to 6 months. As the treatment effect begins to wane, IOP-lowering can be rescued with a repeat injection. Aqueous humor dynamic studies revealed an increase in outflow facility as the mechanism of action. This first-in-class therapeutic approach has the potential to improve care and reduce the rates of vision loss in the 80 million people worldwide currently affected by glaucoma. |
format | Online Article Text |
id | pubmed-9154118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-91541182022-06-01 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility Roddy, Gavin W. Roy Chowdhury, Uttio Anderson, Kjersten J. Rinkoski, Tommy A. Hann, Cheryl R. Chiodo, Vince A. Smith, W. Clay Fautsch, Michael P. PLoS One Research Article Glaucoma is the leading cause of irreversible blindness worldwide. Therapies for glaucoma are directed toward reducing intraocular pressure (IOP), the leading risk factor and only reliable therapeutic target via topical medications or with procedural intervention including laser or surgery. Though topical therapeutics are typically first line, less than 50% of patients take drops as prescribed. Sustained release technologies that decrease IOP for extended periods of time are being examined for clinical use. We recently identified Stanniocalcin-1, a naturally occurring hormone, as an IOP-lowering agent. Here, we show that a single injection into the anterior chamber of mice with an adeno-associated viral vector containing the transgene of stanniocalcin-1 results in diffuse and sustained expression of the protein and produces IOP reduction for up to 6 months. As the treatment effect begins to wane, IOP-lowering can be rescued with a repeat injection. Aqueous humor dynamic studies revealed an increase in outflow facility as the mechanism of action. This first-in-class therapeutic approach has the potential to improve care and reduce the rates of vision loss in the 80 million people worldwide currently affected by glaucoma. Public Library of Science 2022-05-31 /pmc/articles/PMC9154118/ /pubmed/35639753 http://dx.doi.org/10.1371/journal.pone.0269261 Text en © 2022 Roddy et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Roddy, Gavin W. Roy Chowdhury, Uttio Anderson, Kjersten J. Rinkoski, Tommy A. Hann, Cheryl R. Chiodo, Vince A. Smith, W. Clay Fautsch, Michael P. Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
title | Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
title_full | Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
title_fullStr | Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
title_full_unstemmed | Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
title_short | Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
title_sort | transgene expression of stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154118/ https://www.ncbi.nlm.nih.gov/pubmed/35639753 http://dx.doi.org/10.1371/journal.pone.0269261 |
work_keys_str_mv | AT roddygavinw transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT roychowdhuryuttio transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT andersonkjerstenj transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT rinkoskitommya transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT hanncherylr transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT chiodovincea transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT smithwclay transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility AT fautschmichaelp transgeneexpressionofstanniocalcin1providessustainedintraocularpressurereductionbyincreasingoutflowfacility |